Tulio Bertorini, MD
Neurology · Memphis, TNNPI 1760459168
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,542 of the $160,022 with a category attached, or 78.5%. 52 manufacturers reported payments, led by AstraZeneca at 43.7% of the total. Reporting peaked in 2019 at $42,511 and has fallen 50.5% since, to $21,033 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 728 payments — averaging $219.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$70K
- Argenx US, Inc.$26K
- UCB, Inc.$24K
- Sarepta Therapeutics, Inc.$9K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Grifols USA, LLC$7K
- plus $16K from 46 others
Across 141 payments — averaging $6200.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$487K
- Mitsubishi Tanabe Pharma Development America, Inc.$200K
- Tanabe Pharma America, Inc.$60K
- Catalyst Pharmaceuticals, Inc.$35K
- AstraZeneca$27K
- UCB SA$26K
- plus $38K from 6 others
What the payments were for
- Consulting fees$12,6838%
- Speaking & faculty fees$125,54278%
- Travel & lodging$9,6496%
- Food & beverage$11,8067%
- Education$3420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$30,264
- ULTOMIRIS$26,631
- VYVGART$24,813
- Rystiggo$12,245
- Zilbrysq$11,276
- HYQVIA$8,767
- Gamunex-C$6,815
- Exondys 51$5,694
- DISEASE STATE$2,583
- Radicava$1,813
- Hizentra$1,622
- Privigen$1,499
- EXSERVAN$1,100
- Radicava ORS$1,100
- Tiglutik$201
How this compares
$160,022 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 243 | $3,435,689 |
| SolirisEculizumab | 32 | $1,092,481 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 69 | $753,107 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 88 | $467,816 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 32 | $415,475 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 41 | $404,872 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $388,638 |
| SkyclarysOmaveloxolone | 12 | $375,337 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 27 | $372,943 |
| EvrysdiRisdiplam | 13 | $361,788 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 59 | $259,921 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $192,460 |
| NuplazidPimavanserin Tartrate | 13 | $64,970 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $21,146 |
| Riluzole | 151 | $16,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $70,010 | $1,092,48132 claims |
| CSL BehringHizentra, Privigen | $1,957 | $648,55985 claims |
| Grifols USA, LLCGamunex-C | $6,880 | $467,81688 claims |
| PfizerOctagam | $78 | $404,87241 claims |
| BiogenSkyclarys | $354 | $375,33712 claims |
| Genentech USA, Inc.Evrysdi | $143 | $361,78813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $8,807 | $192,46019 claims |
| Acadia Pharmaceuticals IncNuplazid | $212 | $64,97013 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Rytary, Mycophenolate Mofetil | $61 | $27,460223 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $287 | $21,14613 claims |
| UCB, Inc.Neupro | $24,045 | $11,53612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Memphis
- Lucas ElijovichMemphis$415K
- Mark LedouxMemphis$352K
- Khalid AlsherbiniMemphis$249K
- Andrei AlexandrovMemphis$225K
- Rozita KhaliliMemphis$91K
- Michael LevinMemphis$47K
- Michael JacewiczMemphis$33K
- James WangMemphis$27K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.